Press releases | GSK US
US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
Press releases - GSK
European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK lifts annual forecasts again, powered by strong vaccine launch
Nov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
GSK posts blowout RSV vaccine sales, raises outlook - CNBC
Jan 31, 2024 · GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked...
GSK raises profit outlook on strong vaccine, HIV drug sales
May 1, 2024 · GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
GSK plc (GSK) Latest Press Releases & Corporate News - Yahoo …
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
For media and investors only - GSK
Jun 23, 2021 · At an update to investors today, GlaxoSmithKline plc (GSK LSE & NYSE) will provide details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business.
GSK raises annual profit forecasts after strong vaccine sales
Nov 1, 2023 · GSK has lifted its full-year profit forecast after the world’s first jab for the respiratory syncytial virus (RSV) helped power a strong third quarter of vaccine sales at the UK drugmaker.